New Autoimmune Drug AK1940 Enters Trials with Precision Targeting

KAWASAKI, Japan – April 20, 2026 – A new potential therapy for autoimmune diseases has taken a critical step forward, as Japanese biopharmaceutical company PeptiDream Inc. announced its partner, Asahi Kasei Therapeutics, has initiated a Phase 1 clinical trial for a novel drug candidate, AK1940. The compound, a highly selective inhibitor of TNF receptor 1 (TNFR1), represents a new wave of precision-targeted therapies that aim to overcome the limitations of existing treatments for conditions like rheumatoid arthritis and Crohn's disease.

This milestone marks a significant validation for PeptiDream's proprietary drug discovery technology and highlights a nearly decade-long collaboration that could reshape the treatment landscape for millions of patients worldwide suffering from chronic inflammatory disorders.

A More Precise Weapon Against Inflammation

The market for autoimmune disease treatments is dominated by blockbuster drugs like Humira (adalimumab) and Enbrel (etanercept). These therapies, known as TNF-α inhibitors, have provided life-changing relief for many patients by blocking tumor necrosis factor-alpha (TNF-α), a key protein that drives inflammation. However, their broad mechanism comes with a significant downside. By blocking TNF-α entirely, they inhibit its interaction with both of its receptors, TNFR1 and TNFR2. While TNFR1 is primarily responsible for the pro-inflammatory signals that cause tissue damage, TNFR2 is believed to play a role in immune regulation and tissue repair.

This indiscriminate blockade can lead to a compromised immune system, leaving patients vulnerable to serious infections, including the reactivation of latent tuberculosis. The FDA-mandated 'black box' warnings on these drugs also highlight an increased risk of certain cancers, such as lymphoma. AK1940 aims to sidestep these issues with a more sophisticated approach. As a highly selective inhibitor, it is designed to block only TNFR1, theoretically suppressing the harmful inflammation while leaving the potentially beneficial functions of TNFR2 intact.

“The TNF pathway is known to play a critical role in numerous inflammatory, autoimmune, and immune-related diseases, and anti-TNF antibodies are already widely used in clinical practice,” said Patrick C. Reid, President of PeptiDream, in a statement. “A highly selective TNFR1 inhibitor such as AK1940 holds the potential to suppress inflammation in a more targeted way, which may offer a favorable safety and efficacy profile.”

If successful in clinical trials, AK1940 could offer a powerful new option for patients who do not respond to existing therapies or who suffer from their significant side effects, addressing a critical unmet need in a market valued at over $150 billion.

PeptiDream's Platform Technology Proves Its Mettle

The advancement of AK1940 into human trials serves as a major proof point for PeptiDream’s innovative Peptide Discovery Platform System (PDPS®). This sophisticated technology allows for the rapid creation and screening of immense libraries containing trillions of unique macrocyclic peptides—a promising class of drugs that combines the high selectivity of large-molecule biologics with the tissue-penetrating potential of small-molecule drugs.

Macrocyclic peptides have been gaining significant traction in the pharmaceutical industry. Recent approvals, such as Zilucoplan for the autoimmune disorder generalized myasthenia gravis, have demonstrated the therapeutic viability and commercial potential of this drug class. AK1940's discovery through the PDPS® platform reinforces the system's power as a robust engine for generating novel drug candidates against challenging biological targets.

For PeptiDream, the initiation of this trial triggers an undisclosed milestone payment from Asahi Kasei Therapeutics. More importantly, it solidifies a business model built on leveraging its powerful discovery platform through strategic partnerships. The company is also entitled to receive future payments as AK1940 progresses through further clinical stages, as well as royalties on sales if the drug is ultimately approved.

The Power of a Strategic Alliance

The journey of AK1940 from a laboratory concept to a clinical-stage asset is a testament to the successful partnership between PeptiDream and Asahi Kasei Therapeutics. The collaboration, which began in March 2016, paired PeptiDream's cutting-edge peptide discovery capabilities with Asahi Kasei's deep expertise and strategic focus on developing treatments for autoimmune diseases, kidney diseases, and other complex conditions.

This model of R&D, where a specialized biotech provides the discovery engine and a larger pharmaceutical partner shepherds the candidate through the costly and complex clinical development process, is becoming increasingly prevalent. It allows for a sharing of risk and a combination of complementary strengths, accelerating the pace of innovation.

For Asahi Kasei Therapeutics, AK1940 aligns perfectly with its long-term strategy to build a robust pipeline in immunology and contribute to the growth of its pharmaceuticals business. The Phase 1 trial, registered in Japan, will primarily evaluate the safety, tolerability, and pharmacokinetic profile of AK1940 in healthy volunteers. The data gathered from this initial study will be crucial for determining the drug's future development path and its potential application across a broad range of autoimmune disorders.